The Virtual Press Room is a courtesy for corporate and institutional public relations professionals. Publication of material on this page does not constitute an endorsement by ASCO of any product or claim. For information about how to submit a press release to the Virtual Press Room, visit the For PR Professionals page.

2020 ASCO Annual Meeting

ANZUP Cancer Trials
New class of targeted radioactive treatment effective for men with metastatic prostate cancer

BostonGene
BostonGene Announces Acceptance of Abstracts to the Annual Meeting of the American Society of Clinical Oncology 2020

CellWorks
Cellworks SingulaTM Predicts Personalized Therapy Responses for Pancreatic Cancer Patients with 94% Accuracy
Cellworks SingulaTM Predicts Personalized Therapy Responses for AML and MDS Patients with Higher Accuracy than Physician Prescribed Treatments
myCare Clinical Studies Show Cellworks Singulaä Achieves Superior Therapy Response Predictions for Brain Cancer Patients

CytomX Therapeutics
CytomX Therapeutics Announces Details of Presentations at the American Society of Clinical Oncology ASCO20 Virtual Scientific Program

ECOG-ACRIN Cancer Research Group
Trial E3311 validates a less intense treatment for HPV+ throat cancer
Durvalumab added to standard chemotherapy improved overall survival in mesothelioma

Exelixis
EXELIXIS ANNOUNCES RESULTS FROM COSMIC-021 TRIAL OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB IN MULTIPLE ADVANCED SOLID TUMOR TYPES

Foundation Medicine Inc.
Foundation Medicine and Collaborators to Share New Data During the ASCO20 Virtual Scientific Program Showcasing the Importance of Comprehensive Genomic Profiling (CGP) in Informing Advanced Cancer Clinical Decision-Making

Galera Therapeutics
Galera Therapeutics Announces New Data from the Phase 2b Trial on the Effect of Avasopasem Manganese on Cisplatin-Induced Chronic Kidney Disease to be Presented at ASCO 2020 Virtual Scientific Program 

Genentech and Roche
GENENTECH TO PRESENT FIRST CLINICAL  DATA  ON NOVEL ANTI-TIGIT  CANCER  IMMUNOTHERAPY  TIRAGOLUMAB  AT  ASCO

Imperial College London
PROSTAGRAM: 15-MINUTE SCAN THAT COULD UNMASK AGGRESSIVE PROSTATE CANCER EARLIER

Intensity Therapeutics
Intensity Therapeutics’ Abstract (#3016) Selected for Oral Presentation as Part of a Poster Discussion Session at ASCO 2020

Polynoma
Polynoma Presenting Final Analysis of MAVIS Phase III Part B1 Data  of Its Investigational Melanoma Vaccine, Seviprotimut-L, at ASCO20 Virtual Scientific Program

VolitionRx
VolitionRx To Present First Data on Nu.Q™ Capture Performance and Nu.Q™ Assay Performance in Lung Cancer and Blood Cancer at the 2020 ASCO Annual Meeting